Research

Area 3

Liver transplantation and graft viability

Team leader

  • Miquel Navasa
    (Hospital Clínic)

Strategic objectives

Investigation of clinical, mechanistic and therapeutic aspects of liver transplantation. From Hepatic ischemia-reperfusion damage and liver graft viability, to immunosuppression.

Main lines of research

  1. Hepatic ischemia-reperfusion damage and liver graft viability in different models: experimental liver transplantation in the pig with whole or partial grafts, or grafts obtained from donors in asystolia; and liver transplantation in humans. The main objective of this line of research is to define the mechanisms of damage and to design beneficial strategies in the clinical setting.
  2. Immunosuppression, with special interest in three fields: immune tolerance of the allograft, biomarkers of the effects of immunosuppressive drugs, and identification of populations with different risks of rejection. The main objective of this line of research is to suit the immunosuppression after liver transplantation to the real needs of each individual patient.

Research Group

Protective strategies against hepatic ischemia-reperfusion injury

Carmen Peralta

(IDIBAPS)

The investigations led by Carmen Peralta are pioneers in the study of experimental surgical and pharmacological strategies (in vivo pharmacological treatments, improvements in preservation solutions and ischemic preconditioning) that protect livers against damage induced by ischemiareperfusion and increase the tolerance of steatotic livers and reduced-size liver grafts against the risk that show these liver types to damage and regenerative failure when they are submitted to transplantation or hepatic resections.